A systematic review of the effectiveness of adalimumab

TABLE 65 Sensitivity analyses: TNF inhibitors at the start
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
Health Technology Assessment 2006; Vol. 10: No. 42
Scenario Adal – Base Etan – Base Adal+MTX – Etan+MTX – Infl+MTX –
Base Base Base
Base case 52,600 49,400 171,000 78,100 654,000
No HAQ progression on TNF inhibitors 27,000 23,500 37,600 28,000 46,100
Slow HAQ progression on all DMARDs 108,000 89,500 Base 613,000 Base
Slow HAQ progression on all treatments 122,000 109,000 Base 645,000 Base
Fast HAQ progression on all treatments 92,500 99,500 Base 343,000 Base
No effect of HAQ on mortality 50,500 46,500 211,000 80,700 1,910,000
Mortality ratio 2.73 per unit HAQ 62,300 55,300 125,000 77,400 433,000
Effectiveness of conventional DMARDs
down 50%
34,700 30,400 39,300 32,100 44,600
Effectiveness of conventional DMARDs
up 50%
115,000 119,000 Base Base Base
Survival times on conventional DMARDs
down 50%
40,300 36,900 104,000 55,600 227,000
Survival times on conventional DMARDs
up 50%
60,500 56,900 151,000 86,800 605,000
Survival times on TNF inhibitors down 50% 53,400 48,300 Base 177,000 Base
Survival times on TNF inhibitors up 50% 54,900 50,700 92,300 66,800 166,000
Review at 12 weeks 53,500 48,900 195,000 81,500 2,190,000
Short-term quitters on TNF inhibitors
down 50%
56,000 50,400 167,000 79,600 833,000
Short-term quitters on TNF inhibitors
up 50%
50,500 48,100 161,000 75,700 518,000
Short-term quitters on conventional
DMARDs down 50%
53,400 49,500 139,000 74,700 345,000
Short-term quitters on conventional
DMARDs up 50%
50,800 47,000 198,000 79,800 2,950,000
Include offset costs 53,100 48,100 166,000 77,900 827,000
Base: baseline option dominates option with TNF inhibitor.
109